Precision Medicine in Oncology® | Specialty

Tumor Profiling Studies Illuminate Nuances Across Malignancies

November 21st 2022

Molecular and immune landscapes for solid tumors are constantly evolving as precision medicine techniques become more sensitive and next-generation sequencing methods are taken up in clinical practice.

FDA Grants Orphan Drug Designation to Vebreltinib for NSCLC With MET Aberrations

November 17th 2022

The FDA has granted an orphan drug designation to vebreltinib for the treatment of patients with non–small cell lung cancer harboring MET genomic tumor aberrations.

FDA Approves First IHC Companion Diagnostic for Mirvetuximab Soravtansine in Ovarian Cancer

November 15th 2022

The FDA has approved the VENTANA FOLR1 RxDx assay, the first immunohistochemistry companion diagnostic test to help identify patients with epithelial ovarian cancer who are eligible for treatment with mirvetuximab soravtansine-gynx.

Prostate Cancer Has High Rate of Actionable Mutations, Underscoring Need for Testing

November 12th 2022

All patients with prostate cancer, except for those with low-risk or very low-risk localized disease, should be tested for germline mutations, and somatic testing should be done in all patients with metastatic disease as there are therapeutic implications.

Genetic Testing Proves Significant in Identifying Somatic and Germline Mutations in Prostate Cancer

November 11th 2022

As the role of genetic testing in clinical practice becomes more prevalent for patients with prostate cancer to identify mutations, physicians must consider a variety of factors to determine which patients are candidates for somatic and/or germline testing.

Shore Unpacks Treatment Advances for Patients With Urologic Cancers

November 11th 2022

Neal Shore, MD, FACS, highlights the effect of genetic testing on the treatment paradigm of prostate cancer and the evolving treatment landscape for metastatic castration resistant prostate cancer.

Neoantigen TCR T-cell Therapy Shows Early Proof-of-Concept in Solid Tumors

November 10th 2022

A personalized neoantigen-specific and off-the-shelf T cell receptor T-cell therapy utilized through CRISPR gene editing technology demonstrated feasibility and tolerability in 16 patients across multiple tumor types, according to first-in-human phase 1a findings.

Novel Targeted Immunotherapies in Multiple Myeloma, With a Focus on Bispecific Antibodies

November 10th 2022

Milademetan Shows Early Activity in MDM2-Amplified Advanced Solid Tumors

November 10th 2022

Milademetan monotherapy demonstrated preliminary antitumor activity in patients with MDM2-amplified and p53 wild-type advanced solid tumors.

DREAMSeq Trial Clarifies Treatment Sequencing in BRAF V600–Mutant Melanoma

November 8th 2022

Immunotherapy followed by targeted therapy has emerged as the new standard of care for patients with melanoma with BRAF V600 mutations.

Dr. DiSilvestro on the Long-Term OS Benefit of Olaparib Maintenance in Ovarian Cancer

October 24th 2022

Paul A. DiSilvestro, MD, discusses the long-term survival benefit of olaparib maintenance in advanced BRCA-mutated ovarian cancer.

Dr. McKenzie on Navigating the Landscape of Biomarker Testing in NSCLC

October 24th 2022

Andrew McKenzie, PhD, discusses the variety of molecular testing modalities in patients with metastatic non–small cell lung cancer.

ctDNA Helps Predict Recurrence in Real-World Analysis of Patients With Resected CRC

October 21st 2022

Stacey A. Cohen, MD, discusses the results of real-world analysis of patients with resected stage I-III colorectal cancer, how circulating tumor DNA status correlated with recurrence rates, and how these real-world data compared with previous observational studies.

A Newly Identified Genetic Mutation May Be Key to Developing Thymic Cancer Treatment

October 19th 2022

Recent developments in cancers of the thymus, a small organ located in the mediastinum above the heart, have shined a light on a malignancy that only affects about 400 Americans annually.

Futibatinib Approval Expands Options for Patients With FGFR2+ Cholangiocarcinoma

October 19th 2022

The accelerated approval of the FGFR inhibitor futibatinib on September 30, 2022, has expanded options for previously treated adult patients with unresectable, locally advanced, or metastatic intrahepatic cholangiocarcinoma FGFR2 fusions or rearrangements.1

Dr. Yorio on the Safety of Targeted Therapies in BRAF-Mutated Melanoma

October 18th 2022

Jeff Yorio, MD, discusses adverse effects associated with targeted agents and combinations in BRAF-mutated melanoma.

Dr. Bhalla on Unmet Needs in the Treatment of EGFR Exon 20–Mutant NSCLC

October 17th 2022

Sheena Bhalla, MD, discusses the need for improved understanding of EGFR exon 20 insertion mutations in the development of non–small cell lung cancer treatment.

Dr. Yorio on Treatment Combinations in BRAF-Mutated Melanoma

October 13th 2022

Jeff Yorio, MD, discusses treatment combinations in BRAF-mutated melanoma.

Targeted Therapy Combinations Provide Multiple Treatment Options in BRAF-Mutated Melanoma

October 12th 2022

Jeff Yorio, MD, discussed the decision-making process for treating patients with BRAF-mutant melanoma, the use of immunotherapy in melanoma, and the management of cutaneous squamous cell carcinoma and basal cell carcinoma.

Gilteritinib Induces Encouraging Responses in Newly Diagnosed FLT3-Mutated AML

October 9th 2022

Gilteritinib, in combination with induction and consolidation chemotherapy, generated responses in patients with newly diagnosed acute myeloid leukemia, including those with FLT3 mutations, according to data from a phase 1 trial.